Biotech entity
Every one of those 1 sits in a single category, pharma. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Daniel Kohen appears in 1 tracked Biotech story from March 9, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. China is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Daniel Kohen appears in 1 tracked Biotech story from March 9, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Daniel Kohen. Shared-story counts are live from our verified record — not editorial picks.
A new Morgan Stanley report identifies 'affordability politics' as a primary risk for the pharmaceutical sector ahead of the 2026 midterm elections. The firm warns that targeted legislative measures to lower prescription drug costs could create significant pricing pressure on high-margin brand-name drugs.
Daniel Kohen is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
